HSBC Holdings’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$415K Buy
43,966
+25,338
+136% +$227K ﹤0.01% 2370
2026
Q1
$149K Sell
18,628
-40,153
-68% -$364K ﹤0.01% 2683
2025
Q4
$394K Buy
+58,781
New +$443K ﹤0.01% 2413
2025
Q2
Sell
-17,814
Closed -$115K 3172
2025
Q1
$115K Sell
17,814
-117
-0.7% -$967 ﹤0.01% 2775
2024
Q4
$144K Buy
17,931
+7,344
+69% +$70.8K ﹤0.01% 2809
2024
Q3
$137K Sell
10,587
-12,678
-54% -$164K ﹤0.01% 2729
2024
Q2
$296K Buy
23,265
+319
+1% +$3.21K ﹤0.01% 2293
2024
Q1
$110K Buy
22,946
+8,185
+55% +$38K ﹤0.01% 2828
2023
Q4
$71.5K Hold
14,761
﹤0.01% 2626
2023
Q3
$108K Sell
14,761
-4,100
-22% -$32.8K ﹤0.01% 2539
2023
Q2
$142K Sell
18,861
-947
-5% -$7.45K ﹤0.01% 2387
2023
Q1
$135K Sell
19,808
-1,255
-6% -$11.5K ﹤0.01% 2465
2022
Q4
$205K Sell
21,063
-16,102
-43% -$284K ﹤0.01% 2763
2022
Q3
$693K Sell
37,165
-626
-2% -$27.1K ﹤0.01% 2010
2022
Q2
$1.97M Sell
37,791
-52,681
-58% -$2.73M ﹤0.01% 1592
2022
Q1
$6.66M Sell
90,472
-919,774
-91% -$82M 0.01% 1073
2021
Q4
$148M Buy
1,010,246
+983,434
+3,668% +$169M 0.14% 124
2021
Q3
$5.59M Buy
26,812
+5,825
+28% +$1.28M 0.01% 1105
2021
Q2
$4.45M Buy
20,987
+16,348
+352% +$3M ﹤0.01% 1147
2021
Q1
$835K Sell
4,639
-7,325
-61% -$1.46M ﹤0.01% 1697
2020
Q4
$1.35M Buy
11,964
+9,961
+497% +$1.06M ﹤0.01% 1512
2020
Q3
$221K Sell
2,003
-4,287
-68% -$522K ﹤0.01% 2412
2020
Q2
$524K Buy
+6,290
New +$241K ﹤0.01% 1809
2019
Q2
Sell
-1,336
Closed -$15K 2811
2019
Q1
$15K Buy
+1,336
New +$42.2K ﹤0.01% 2684
2017
Q1
Sell
-2,326
Closed -$59K 2438
2016
Q4
$59K Buy
+2,326
New +$67.8K ﹤0.01% 2656
2015
Q3
Sell
-640
Closed -$143K 2094
2015
Q2
$143K Buy
640
+87
+16% +$15.3K ﹤0.01% 1881
2015
Q1
$91K Sell
553
-76
-12% -$12.3K ﹤0.01% 1996
2014
Q4
$75K Buy
+629
New +$65.7K ﹤0.01% 1747

Other funds holding NVAX

HSBC Holdings's NVAX Position: Q2 2026 in Review

HSBC Holdings increased its Novavax (NVAX) stake by 136% in Q2 2026, buying an estimated $227K and bringing the position to 43,966 shares worth $415K. The position accounts for ﹤0.01% of the portfolio, ranked #2370.

HSBC Holdings first reported a position in NVAX in Q4 2014 and has held it in 28 quarters since. The position peaked at $148M in Q4 2021. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • HSBC Holdings held 43,966 shares of Novavax worth $415K as of Q2 2026.
  • HSBC Holdings bought 25,338 Novavax shares in Q2 2026, an estimated $227K.
  • Novavax made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2370 holding.
  • HSBC Holdings first reported a position in Novavax in Q4 2014 and has held it in 28 quarters since.
  • HSBC Holdings's Novavax position peaked at $148M in Q4 2021.
  • 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.